

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel.: (91-22) 4324 4324
Fax: (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



August 31, 2024

National Stock Exchange of India Limited
Scrp Symbol: SUNPHARMA

BSE Limited
Scrp Code: 524715

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Regulatory Order

This is to inform that the Company has received an order passed by statutory authority. Relevant details, as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, are provided in Annexure A.

The Company shall take appropriate action in the matter.

For **Sun Pharmaceutical Industries Limited**

(Anoop Deshpande)
Company Secretary and Compliance Officer
ICSI Membership No.: A23983

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel.: (91-22) 4324 4324
Fax: (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050

**Annexure A****Disclosure under Para (A) of Part (A) of Schedule III to the Regulation 30 SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015**

Sl. No.	Particulars	Information												
a)	Name of the authority	Regional Director, North Western Region, Ministry of Corporate Affairs												
b)	Nature and details of the action(s) taken, initiated, or order(s) passed	Interim order passed in the matter of application of compounding of offences under Section 441 for alleged offences under Section 177 of the Companies Act, 2013. A penalty of INR 9,60,000 (Rupees Nine Lakh Sixty Thousand only) is imposed on the Company and its directors as follows. <table border="1" style="margin-left: auto; margin-right: auto;"> <thead> <tr> <th colspan="2" style="text-align: center;">Amount in INR</th> </tr> </thead> <tbody> <tr> <td>Sun Pharmaceutical Industries Limited</td> <td style="text-align: right;">4,80,000</td> </tr> <tr> <td>Mr. Dilip Shanghvi</td> <td style="text-align: right;">1,20,000</td> </tr> <tr> <td>Mr. Sailesh Desai</td> <td style="text-align: right;">1,20,000</td> </tr> <tr> <td>Mr. Sudhir Valia</td> <td style="text-align: right;">1,20,000</td> </tr> <tr> <td>Mr. K. Subramanian</td> <td style="text-align: right;">1,20,000</td> </tr> </tbody> </table>	Amount in INR		Sun Pharmaceutical Industries Limited	4,80,000	Mr. Dilip Shanghvi	1,20,000	Mr. Sailesh Desai	1,20,000	Mr. Sudhir Valia	1,20,000	Mr. K. Subramanian	1,20,000
Amount in INR														
Sun Pharmaceutical Industries Limited	4,80,000													
Mr. Dilip Shanghvi	1,20,000													
Mr. Sailesh Desai	1,20,000													
Mr. Sudhir Valia	1,20,000													
Mr. K. Subramanian	1,20,000													
c)	Date of receipt of direction or order, including any ad-interim or interim orders or any other communication from the authority	August 30, 2024												
d)	Details of the violation(s)/ contravention(s) Committed or alleged to be committed	<p>This matter pertains to the earlier investigation carried out by SEBI, in which a Settlement was reached with SEBI in February 2021 without admission or denial of guilt; however, on the same matter, the Ministry of Corporate Affairs also initiated an investigation in parallel in 2019.</p> <p>Interim order in the application for compounding of offences for alleged violation under Section 177 for failure to take approval of the Audit Committee for a related party transaction with Aditya Medisales Limited for the financial years 2014-15 to 2017-18.</p> <p>For the subsequent period, the related party transactions with Aditya Medisales Limited were duly approved by the Audit Committee and, based on its recommendation, approved by the</p>												

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.

Tel.: (91-22) 4324 4324

Fax: (91-22) 4324 4343

Website: www.sunpharma.com

Email: secretarial@sunpharma.com

CIN: L24230GJ1993PLC019050



		shareholders with a 92.9% majority.
e)	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	There is no material impact on the Company's financial, operation or other activities.